AKTIS ONCOLOGY INC
AKTSNASDAQ🏆 #2423 by market capEarnings Nov 12US Equity
$19.59▼ $0.10 (−0.52%)
LiveTrack AKTS
Get earnings, price moves & breaking news on Telegram
24h▼ 0.5%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$1.05B
Small Cap
📈Revenue Growth (YoY)
+49.9%
High Growth
📊Gross Margin
-11.6%
Thin
💵FCF Margin
—
⚖️P/S Ratio
82.4x
Expensive
Otter Score
80
Good
AKTIS ONCOLOGY INC
AKTSAnalyst Ratings
Price
$19.59
Total
8
Raised
0
Lowered
2
Avg PT
$37.40
H / L
$40 / $35
| Institution | Action | Rating | Date | Upside | |
|---|---|---|---|---|---|
JP Morgan | Reiterated | Overweight | 2026-07-14 | — | — |
HC Wainwright & Co. | Reiterated | Buy | 2026-06-02 | — | — |
Piper Sandler | Downgraded | Overweight → Neutral | 2024-01-04 | — | — |
B. Riley Securities | Downgraded | Buy → Neutral | 2023-09-07 | — | — |
Oppenheimer | Reiterated | Outperform | 2023-09-07 | $40.00 | +104.20% |
Roth MKM | Reiterated | Buy | 2023-05-09 | — | — |
Roth Capital | Reiterated | Buy | 2021-05-04 | — | — |
Northland Capital Markets | Reiterated | Market Perform | 2019-12-20 | — | — |
Institution
JP Morgan
Reiterated · Overweight · 2026-07-14
—
—
HC Wainwright & Co.
Reiterated · Buy · 2026-06-02
—
—
Piper Sandler
Downgraded · Overweight → Neutral · 2024-01-04
—
—
B. Riley Securities
Downgraded · Buy → Neutral · 2023-09-07
—
—
Oppenheimer
Reiterated · Outperform · 2023-09-07
$40.00
+104.20%
Roth MKM
Reiterated · Buy · 2023-05-09
—
—
Roth Capital
Reiterated · Buy · 2021-05-04
—
—
Northland Capital Markets
Reiterated · Market Perform · 2019-12-20
—
—
One row per institution · price target from the firm's latest published target
StockOtter · stockotter.space